Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea
· Delayed Price · Currency is KRW 10,890
+10 (0.09%)
Apr 1, 2025, 3:30 PM KST
Hyundai Bioscience Revenue
In the year 2024, Hyundai Bioscience had annual revenue of 15.05B KRW with 58.73% growth. Hyundai Bioscience had revenue of 365.54M in the quarter ending December 31, 2024, a decrease of -67.76%.
Revenue
15.05B
Revenue Growth
+58.73%
P/S Ratio
28.82
Revenue / Employee
278.70M
Employees
54
Market Cap
522.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15.05B | 5.57B | 58.73% |
| Dec 31, 2023 | 9.48B | 1.63B | 20.76% |
| Dec 31, 2022 | 7.85B | -1.39B | -15.04% |
| Dec 31, 2021 | 9.24B | -3.27B | -26.14% |
| Dec 31, 2020 | 12.51B | -17.57B | -58.41% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |